Strong Gross Business Awards
Gross business awards totaled $3 billion, up mid-single digits year-over-year, with notable strength in oncology, cardiometabolic disease, and FSP sectors.
Share Repurchase Program
Bought back $250 million in shares during Q3, bringing total repurchases to $750 million year-to-date.
Positive Biotech Sector Performance
Significant increase in RFP flow in the biotech sector on a year-over-year and sequential basis, reflecting improved funding environment.
Revenue and Earnings Growth
Revenue increased sequentially and year-over-year, with adjusted earnings per share of $3.31, a 1.5% increase over Q2.
Strong Free Cash Flow
Generated $334 million in free cash flow during Q3 and $687 million year-to-date.
Strategic Investments in Technology
Continued focus on deploying innovative technologies, including AI-enabled tools, to enhance efficiency and predictability in clinical trials.